MYGN · Myriad Genetics, Inc. · Stock research

Current Thesis

Myriad is a legacy hereditary-cancer testing house (BRACAnalysis, GeneSight, Prolaris) trying to re-rate through a diagnostics pivot into minimal-residual-disease (MRD/ctDNA) and AI-enhanced oncology. Since the June dossier the tape has changed character: shares ran roughly +40% from the June $3.99 low to a $6.26 high (July 6) and now consolidate near $6.18 (July 17), reclaiming the 52-week midpoint after months of value-trap structure. The bounce has real catalysts behind it — Prolaris + AI launched May 26, the Precise MRD colorectal/renal launch was pulled forward to Q3, and a July 2 meta-analysis reinforced the Prolaris data. What it does not yet have is accelerating fundamentals: core revenue grew ~2% YoY in Q1 with negative EBITDA. The structure has repaired, but the name is now extended into a binary August 4 Q2 print, with the Street Hold-rated and price sitting right at the consensus target. A recovery base worth watching, not a fresh accelerating entry to chase.

Bullish and bearish views on Myriad Genetics, Inc.

The model's bull view on Myriad Genetics, Inc. (MYGN), in brief: Prolaris + AI shipped on schedule (May 26, 2026). The bear view: Decelerating core, negative EBITDA. Q1 (May 5): revenue $200.4M, +2% YoY and a hair light of ~$202.4M consensus; adjusted EPS -$0.09 missed the -$0.07 estimate; adjusted EBITDA -$4.5M; the stock fell ~14% on the print. The recent run is off a depressed base, not off inflecting… Both cases follow in full.

Bull Case

• Prolaris + AI shipped on schedule (May 26, 2026). First prostate test combining genomics with digital-pathology AI; live on all U.S. Prolaris biopsy samples from May 29. Prostate cancer is projected the #1 U.S. diagnosis this year (>300,000 new patients). Prolaris revenue grew 3% YoY in Q1 (May 5).
• July 2, 2026 meta-analysis showed the Prolaris Biopsy Test adds prognostic information beyond conventional clinical risk categories — the kind of evidence that supports active-surveillance guideline and payer positioning.
• MRD roadmap accelerating, not slipping. June 23: Precise MRD expanded to breast/colorectal/renal; on the May 5 call management moved the colorectal + renal select-customer launch forward to Q3 2026 (from 2027), full commercial in 2027. MONITOR-Breast (Future Oncology, June 23): 100% specificity for pCR prediction, 44% more at-risk patients caught longitudinally.
• GeneSight compounding. Mental-health revenue +24% YoY to $38.3M in Q1 (May 5), the fastest-growing segment; FirstGene launch guided for 2H 2026, framed as margin-accretive using existing billing codes.
• Guidance reaffirmed and balance sheet neutral. FY2026 revenue held at $860–880M with 2H > 1H (May 5); $124.4M cash vs $120.3M long-term debt at 3/31. Market cap ~$584M (July 17).
• Structure repaired. +40% off the June $3.99 base with a higher low at $5.88 (July 13); the first sustained trend improvement in over a year.

Bear Case

• Decelerating core, negative EBITDA. Q1 (May 5): revenue $200.4M, +2% YoY and a hair light of ~$202.4M consensus; adjusted EPS -$0.09 missed the -$0.07 estimate; adjusted EBITDA -$4.5M; the stock fell ~14% on the print. The recent run is off a depressed base, not off inflecting numbers.
• Prenatal Health bleeding. -15% YoY to $41.9M in Q1, offsetting cancer growth and pinning consolidated revenue near flat.
• Late entrant in a reimbursement-gated market. Precise MRD trails Natera Signatera (Medicare-covered, scaled), Guardant Reveal and Exact Sciences Oncodetect. Coverage and volume decide MRD winners, and a single publication does not.
• No consensus upside left at the tape. Street is Hold with an average 12-month target near $6.25–$6.50 against a $6.18 close; Wells Fargo cut to $5.50 equal-weight (May 6) and TD Cowen to $6.00 hold (May 6). Estimates drifting sideways-to-down.
• Binary print 17 days out. Q2 earnings August 4; management guided only "low single-digit" sequential Q2 revenue growth — a soft bar under a stock that just ran +40%, with Q1 as a reminder of gap risk.
• Thin liquidity. ~$584M cap, sub-$7 price: single-name news dominates and momentum quality is poor.

Setup & Price Structure

Price $6.18 (July 17), inside a July range of $5.75–$6.26. The sequence: June $3.99 low → $6.26 (July 6) → $5.88 (July 13) → $6.18 — a higher-low consolidation above the 52-week midpoint (~$6.06), within a 52-week band of $3.53–$8.59. The recovery is genuine but the move stalled at $6.26 and is now digesting +40% directly into an earnings binary. RSI sits elevated after the run, and the name trades at its consensus target with no analyst headroom. Buying here is paying up for extension ahead of a print that gapped -14% last quarter. The cleaner re-entry is either a pre-print base that holds above $5.75, or a post-August-4 reaction that confirms the guided 2H acceleration.

Catalyst Calendar (next 30 days)

• Q3 2026 (dated on the May 5 call) — Precise MRD colorectal + renal select-customer launch, pulled forward from 2027; first dated PR here would be the next narrative confirmation.
• 2H 2026 — FirstGene launch, guided margin-accretive.

Elapsed catalysts

• 2026-08-04 — Q2 2026 earnings (confirmed). The binary. Watch: FY guide reaffirmed/raised ($860–880M), explicit 2H > 1H confirmation, and early Precise MRD + Prolaris + AI traction. ~17 days out — treat as an approaching blackout for fresh exposure. (passed 5d ago)

What Would Change Our Mind

A weekly close and hold above $6.26 (the July 6 high) on MRD reimbursement or coverage news would flip the recovery from a bounce to a trend and justify a real entry. On the August 4 print, a reaffirmed or raised guide with confirmed 2H > 1H acceleration and dated MRD traction would de-risk the pivot and warrant sizing up. Conversely, a weekly close below $5.75 breaks the July shelf and re-exposes the $4.00 June base, and a soft print or guide cut would restore the value-trap read the name carried through spring.

Correlation Notes

MYGN moves with the diagnostics/liquid-biopsy complex — Natera (NTRA), Exact Sciences (EXAS), Guardant (GH) — where MRD reimbursement and coverage headlines re-rate the whole group. It carries high beta to biotech risk sentiment (XBI) and to rate-sensitivity in unprofitable small-cap healthcare. Prolaris ties adoption to urology practice channels; GeneSight to psychiatry prescribing. Given the thin ~$584M float, single-name product-launch and earnings-cadence news dominate over sector beta, so the August 4 print is the primary risk event rather than any macro correlate.